NCT07638007
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Recruiting
Not specifiedAges 18+ObservationalUniversity of Rochester NCORP Research BaseInvestigator-initiated
~400 participants
Updated 2026-06-10 on ClinicalTrials.gov
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Subjective cognitive performance
Measured over 12 months
Conditions
NCT07638007
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Rochester NCORP Research Base
Rochester, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Michelle Janelsins, PhD · STUDY_CHAIR · University of Rochester NCORP Research Base
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
TKI RECIPIENTS: Participants must have a diagnosis of CML or CLL
TKI RECIPIENTS: Participants must be scheduled to receive their first dose of TKI therapy for CML or CLL within 30 days or have received their first dose of TKI therapy for CML or CLL within the previous 30 days
TKI RECIPIENTS: Participants must be ≥ 18 years of age
TKI RECIPIENTS: Participants must be able to speak and read English
TKI RECIPIENTS: Participants must be able to understand and willing to sign an informed consent document
CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be ≥ 18 years of age
CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to speak and read English
CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to understand and willing to sign an informed consent document
CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Each participant must be matched to a TKI recipient participant based on sex and age ±5 years (i.e., must be no more than 5 years older or younger than the TKI recipient participant)
Exclusion
Participants must have no history of metastatic cancer, primary brain tumor, or brain irradiation
Participants must have no history of TKI therapy
Participants must have no history of cytotoxic chemotherapy, immune checkpoint inhibitor therapy, hormonal therapy, biologic therapy, radiotherapy within the past 5 years. However, permitted treatments include prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
Participants must have no history of stroke within the past year and no remaining cognitive symptoms from any stroke prior to the past year
Participants must have no history of head trauma with loss of consciousness within the year prior to consent
Participants must have no diagnosis of dementia or severe neurodegenerative disease impairing daily functioning
Participants must have no psychiatric condition that led to hospitalization within the past year
Participants must not be currently pregnant
Participants must not be colorblind based on self-report
Participants must not be study staff who have previously viewed or administered the objective cognitive function measures (e.g., CANTAB)
What this trial measures
- Subjective cognitive performance12 months
Will be assessed using the FACT-Cog. Will apply multilevel models to study data. Will include main effects of time, group, and the group X time interaction.